Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease

Murray E. Hines, Sue E. Turnquist, Marcia R S Ilha, Sreekumari Rajeev, Arthur L. Jones, Lisa Whittington, John P. Bannantine, Raul G Barletta, Yrjö T. Gröhn, Robab Katani, Adel M. Talaat, Lingling Li, Vivek Kapur

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Johne's disease (JD) caused by Mycobacterium avium subspecies paratuberculosis (MAP) is a major threat to the dairy industry and possibly some cases of Crohn's disease in humans. A MAP vaccine that reduced of clinical disease and/or reduced fecal shedding would aid in the control of JD. The objectives of this study were (1) to evaluate the efficacy of 5 attenuated strains of MAP as vaccine candidates compared to a commercial control vaccine using the protocol proposed by the Johne's Disease Integrated Program (JDIP) Animal Model Standardization Committee (AMSC), and (2) to validate the AMSC Johne's disease goat challenge model. Eighty goat kids were vaccinated orally twice at 8 and 10 weeks of age with an experimental vaccine or once subcutaneously at 8 weeks with Silirum® (Zoetis), or a sham control oral vaccine at 8 and 10 weeks. Kids were challenged orally with a total of approximately 1.44 × 109 CFU divided in two consecutive daily doses using MAP ATCC-700535 (K10-like bovine isolate). All kids were necropsied at 13 months post-challenge. Results indicated that the AMSC goat challenge model is a highly efficient and valid model for JD challenge studies. None of the experimental or control vaccines evaluated prevented MAP infection or eliminated fecal shedding, although the 329 vaccine lowered the incidence of infection, fecal shedding, tissue colonization and reduced lesion scores, but less than the control vaccine. Based on our results the relative performance ranking of the experimental live-attenuated vaccines evaluated, the 329 vaccine was the best performer, followed by the 318 vaccine, then 316 vaccine, 315 vaccine and finally the 319 vaccine was the worst performer. The subcutaneously injected control vaccine outperformed the orally-delivered mutant vaccine candidates. Two vaccines (329 and 318) do reduce presence of JD gross and microscopic lesions, slow progression of disease, and one vaccine (329) reduced fecal shedding and tissue colonization.

Original languageEnglish (US)
Article numberArticle 26
JournalFrontiers in Cellular and Infection Microbiology
Volume5
Issue numberMAR
DOIs
StatePublished - Jan 1 2014

Fingerprint

Paratuberculosis
Vaccines
Mycobacterium avium subsp. paratuberculosis
Goats
Animal Models
Dairying
Attenuated Vaccines

Keywords

  • Diagnostic tests
  • Goats
  • Mutant vaccines
  • Mycobacterium avium subsp paratuberculosis
  • Vaccine efficacy

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Hines, M. E., Turnquist, S. E., Ilha, M. R. S., Rajeev, S., Jones, A. L., Whittington, L., ... Kapur, V. (2014). Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease. Frontiers in Cellular and Infection Microbiology, 5(MAR), [Article 26]. https://doi.org/10.3389/fcimb.2014.00026

Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease. / Hines, Murray E.; Turnquist, Sue E.; Ilha, Marcia R S; Rajeev, Sreekumari; Jones, Arthur L.; Whittington, Lisa; Bannantine, John P.; Barletta, Raul G; Gröhn, Yrjö T.; Katani, Robab; Talaat, Adel M.; Li, Lingling; Kapur, Vivek.

In: Frontiers in Cellular and Infection Microbiology, Vol. 5, No. MAR, Article 26, 01.01.2014.

Research output: Contribution to journalArticle

Hines, ME, Turnquist, SE, Ilha, MRS, Rajeev, S, Jones, AL, Whittington, L, Bannantine, JP, Barletta, RG, Gröhn, YT, Katani, R, Talaat, AM, Li, L & Kapur, V 2014, 'Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease', Frontiers in Cellular and Infection Microbiology, vol. 5, no. MAR, Article 26. https://doi.org/10.3389/fcimb.2014.00026
Hines, Murray E. ; Turnquist, Sue E. ; Ilha, Marcia R S ; Rajeev, Sreekumari ; Jones, Arthur L. ; Whittington, Lisa ; Bannantine, John P. ; Barletta, Raul G ; Gröhn, Yrjö T. ; Katani, Robab ; Talaat, Adel M. ; Li, Lingling ; Kapur, Vivek. / Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease. In: Frontiers in Cellular and Infection Microbiology. 2014 ; Vol. 5, No. MAR.
@article{9958baa9f93e4686b6d074f88da2260c,
title = "Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease",
abstract = "Johne's disease (JD) caused by Mycobacterium avium subspecies paratuberculosis (MAP) is a major threat to the dairy industry and possibly some cases of Crohn's disease in humans. A MAP vaccine that reduced of clinical disease and/or reduced fecal shedding would aid in the control of JD. The objectives of this study were (1) to evaluate the efficacy of 5 attenuated strains of MAP as vaccine candidates compared to a commercial control vaccine using the protocol proposed by the Johne's Disease Integrated Program (JDIP) Animal Model Standardization Committee (AMSC), and (2) to validate the AMSC Johne's disease goat challenge model. Eighty goat kids were vaccinated orally twice at 8 and 10 weeks of age with an experimental vaccine or once subcutaneously at 8 weeks with Silirum{\circledR} (Zoetis), or a sham control oral vaccine at 8 and 10 weeks. Kids were challenged orally with a total of approximately 1.44 × 109 CFU divided in two consecutive daily doses using MAP ATCC-700535 (K10-like bovine isolate). All kids were necropsied at 13 months post-challenge. Results indicated that the AMSC goat challenge model is a highly efficient and valid model for JD challenge studies. None of the experimental or control vaccines evaluated prevented MAP infection or eliminated fecal shedding, although the 329 vaccine lowered the incidence of infection, fecal shedding, tissue colonization and reduced lesion scores, but less than the control vaccine. Based on our results the relative performance ranking of the experimental live-attenuated vaccines evaluated, the 329 vaccine was the best performer, followed by the 318 vaccine, then 316 vaccine, 315 vaccine and finally the 319 vaccine was the worst performer. The subcutaneously injected control vaccine outperformed the orally-delivered mutant vaccine candidates. Two vaccines (329 and 318) do reduce presence of JD gross and microscopic lesions, slow progression of disease, and one vaccine (329) reduced fecal shedding and tissue colonization.",
keywords = "Diagnostic tests, Goats, Mutant vaccines, Mycobacterium avium subsp paratuberculosis, Vaccine efficacy",
author = "Hines, {Murray E.} and Turnquist, {Sue E.} and Ilha, {Marcia R S} and Sreekumari Rajeev and Jones, {Arthur L.} and Lisa Whittington and Bannantine, {John P.} and Barletta, {Raul G} and Gr{\"o}hn, {Yrj{\"o} T.} and Robab Katani and Talaat, {Adel M.} and Lingling Li and Vivek Kapur",
year = "2014",
month = "1",
day = "1",
doi = "10.3389/fcimb.2014.00026",
language = "English (US)",
volume = "5",
journal = "Frontiers in cellular and infection microbiology",
issn = "2235-2988",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease

AU - Hines, Murray E.

AU - Turnquist, Sue E.

AU - Ilha, Marcia R S

AU - Rajeev, Sreekumari

AU - Jones, Arthur L.

AU - Whittington, Lisa

AU - Bannantine, John P.

AU - Barletta, Raul G

AU - Gröhn, Yrjö T.

AU - Katani, Robab

AU - Talaat, Adel M.

AU - Li, Lingling

AU - Kapur, Vivek

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Johne's disease (JD) caused by Mycobacterium avium subspecies paratuberculosis (MAP) is a major threat to the dairy industry and possibly some cases of Crohn's disease in humans. A MAP vaccine that reduced of clinical disease and/or reduced fecal shedding would aid in the control of JD. The objectives of this study were (1) to evaluate the efficacy of 5 attenuated strains of MAP as vaccine candidates compared to a commercial control vaccine using the protocol proposed by the Johne's Disease Integrated Program (JDIP) Animal Model Standardization Committee (AMSC), and (2) to validate the AMSC Johne's disease goat challenge model. Eighty goat kids were vaccinated orally twice at 8 and 10 weeks of age with an experimental vaccine or once subcutaneously at 8 weeks with Silirum® (Zoetis), or a sham control oral vaccine at 8 and 10 weeks. Kids were challenged orally with a total of approximately 1.44 × 109 CFU divided in two consecutive daily doses using MAP ATCC-700535 (K10-like bovine isolate). All kids were necropsied at 13 months post-challenge. Results indicated that the AMSC goat challenge model is a highly efficient and valid model for JD challenge studies. None of the experimental or control vaccines evaluated prevented MAP infection or eliminated fecal shedding, although the 329 vaccine lowered the incidence of infection, fecal shedding, tissue colonization and reduced lesion scores, but less than the control vaccine. Based on our results the relative performance ranking of the experimental live-attenuated vaccines evaluated, the 329 vaccine was the best performer, followed by the 318 vaccine, then 316 vaccine, 315 vaccine and finally the 319 vaccine was the worst performer. The subcutaneously injected control vaccine outperformed the orally-delivered mutant vaccine candidates. Two vaccines (329 and 318) do reduce presence of JD gross and microscopic lesions, slow progression of disease, and one vaccine (329) reduced fecal shedding and tissue colonization.

AB - Johne's disease (JD) caused by Mycobacterium avium subspecies paratuberculosis (MAP) is a major threat to the dairy industry and possibly some cases of Crohn's disease in humans. A MAP vaccine that reduced of clinical disease and/or reduced fecal shedding would aid in the control of JD. The objectives of this study were (1) to evaluate the efficacy of 5 attenuated strains of MAP as vaccine candidates compared to a commercial control vaccine using the protocol proposed by the Johne's Disease Integrated Program (JDIP) Animal Model Standardization Committee (AMSC), and (2) to validate the AMSC Johne's disease goat challenge model. Eighty goat kids were vaccinated orally twice at 8 and 10 weeks of age with an experimental vaccine or once subcutaneously at 8 weeks with Silirum® (Zoetis), or a sham control oral vaccine at 8 and 10 weeks. Kids were challenged orally with a total of approximately 1.44 × 109 CFU divided in two consecutive daily doses using MAP ATCC-700535 (K10-like bovine isolate). All kids were necropsied at 13 months post-challenge. Results indicated that the AMSC goat challenge model is a highly efficient and valid model for JD challenge studies. None of the experimental or control vaccines evaluated prevented MAP infection or eliminated fecal shedding, although the 329 vaccine lowered the incidence of infection, fecal shedding, tissue colonization and reduced lesion scores, but less than the control vaccine. Based on our results the relative performance ranking of the experimental live-attenuated vaccines evaluated, the 329 vaccine was the best performer, followed by the 318 vaccine, then 316 vaccine, 315 vaccine and finally the 319 vaccine was the worst performer. The subcutaneously injected control vaccine outperformed the orally-delivered mutant vaccine candidates. Two vaccines (329 and 318) do reduce presence of JD gross and microscopic lesions, slow progression of disease, and one vaccine (329) reduced fecal shedding and tissue colonization.

KW - Diagnostic tests

KW - Goats

KW - Mutant vaccines

KW - Mycobacterium avium subsp paratuberculosis

KW - Vaccine efficacy

UR - http://www.scopus.com/inward/record.url?scp=84898048517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898048517&partnerID=8YFLogxK

U2 - 10.3389/fcimb.2014.00026

DO - 10.3389/fcimb.2014.00026

M3 - Article

C2 - 24624365

AN - SCOPUS:84898048517

VL - 5

JO - Frontiers in cellular and infection microbiology

JF - Frontiers in cellular and infection microbiology

SN - 2235-2988

IS - MAR

M1 - Article 26

ER -